About Contact Us Careers

Prils Market Size and Forecast, by Type (Amipril, Quinapril, Cilazapril, Benazepril), Distribution Channel (Hospital, Pharmacies), Application (Hypertension, Heart Failure, Chronic Kidney Disorder) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 4109
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450

Prils Market Outlook:

Prils Market size was over USD 2.51 billion in 2025 and is poised to exceed USD 4.67 billion by 2035, witnessing over 6.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.

Prils Market overview
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The growth of the market can be attributed to the increasing prevalence of high blood pressure. Lifestyle modifications and appropriate medication, such as prils, are frequently used to treat the disease.

When more people are diagnosed with hypertension and given prescriptions for blood pressure management, in turn, could increase the demand for market. According to estimates over 69 million senior adults in India are expected to have hypertension by the year 2050.

Factors that are believed to fuel the prils market growth include the rise in the pharmaceutical industry across the globe. As more people gain access to the medication, there may be an increase in demand as a result of greater accessibility and availability of prils in hospitals, pharmacies, and other locations.

Key Prils Market Insights Summary:

  • Regional Highlights:

    • North America is anticipated to command a 41% share of the Prils Market by 2035, owing to the increasing cases of obesity.
    • Europe is projected to secure a 31% share by 2035, stemming from rising initiatives that support the expansion of generic medications.

  • Segment Insights:

    • The hypertension segment in the Prils Market is estimated to account for a 50% share by 2035, supported by the increasing cases of hypertension worldwide.
    • The hospital segment is expected to hold a 40% share by 2035, spurred by the growing prevalence of comorbidities among hospitalized patients.

  • Key Growth Trends:

    • Growing Prevalence of Lifestyle Disorders
    • Rising Geriatric Population

  • Major Challenges:

    • The challenge to getting Approval from Regulatory Authorities
    • Development of Fake Medicines by Several Companies

  • Key Players: Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited.

Global Prils Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 2.51 billion
    • 2026 Market Size: USD 2.65 billion
    • Projected Market Size: USD 4.67 billion by 2035
    • Growth Forecasts: 6.4%

  • Key Regional Dynamics:

    • Largest Region: North America (41% Share by 2035)
    • Fastest Growing Region: Europe
    • Dominating Countries: United States, Germany, China, United Kingdom, Japan
    • Emerging Countries: India, Brazil, South Korea, Mexico, United Arab Emirates

    • Last updated on : 21 November, 2025

Growth Drivers

  • Growing Prevalence of Lifestyle Disorders – As more people with lifestyle disorders rely on drugs to manage their illnesses, the prils market is expected to expand more in the upcoming years. According to the WHO, non-communicable diseases, or NCDs—of which lifestyle illnesses are a subset—take the lives of more than 4o million people each year, or more than 65% of all fatalities worldwide.

  • Rising Geriatric Population – Age-related changes in blood vessel flexibility, kidney function, and lifestyle choices all raise the risk of hypertension in older persons. Thus the expanding older population may face a higher prevalence of hypertension, which as a result is estimated to drive market growth. Lately over 8% of the world's population, is over the age of 65. By 2050, this figure is expected to rise by over 15% of the world's population.
  • Growing Incidences of Cardiovascular Diseases – It is expected that CVD can develop as a result of unhealthy lifestyle habits including an unhealthy diet, excessive sitting, and a lack of exercise, which is anticipated to drive the prils market growth. It was discovered that with over 17 million deaths per year, cardiovascular diseases (CVDs) are the leading cause of death worldwide.

Challenges

  • The challenge to getting Approval from Regulatory Authorities - The acquirement of approval for the production and testing of the product is one of the major factors predicted to slow down the market growth. For instance, it could take a lengthy time to obtain regulatory authorities' clearance, which delays the release of the product.

  • Development of Fake Medicines by Several Companies

  • Exorbitant Cost of Drugs

Prils Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

6.4%

Base Year Market Size (2025)

USD 2.51 billion

Forecast Year Market Size (2035)

USD 4.67 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Prils Market Segmentation:

Application (Hypertension, Heart Failure, Chronic Kidney Disorder)

The hypertension segment is estimated to hold 50% share of the global prils market in the year 2035. The growth of the segment can be attributed to the increasing cases of hypertension across the globe. As more individuals with hypertension may need medications to control their blood pressure, this could lead to an increase in demand for market.

Besides prils are frequently combined with other antihypertensive drugs to improve blood pressure control which is further expected to contribute to the market growth. Around 970 million people worldwide, or over 25% of the population, have hypertension, and by 2025, that number is projected to rise by over 28%.

Distribution Channel (Hospital, Pharmacies)

Prils market from the hospital segment is expected to garner a significant share of 40% in the year 2035. Prils may be prescribed in hospitals for patients with comorbidities, such as diabetes or chronic renal disease that are frequently linked to hypertension or heart failure. They may be provided as part of the therapy plan for various comorbidities since many individuals admitted to hospitals may have several medical problems. As a result, the demand for prils in hospitals may be expanding along with the prevalence of these comorbidities. As a consequence, multiple opportunities for the segment's growth are expected in the next years.

Our in-depth analysis of the global prils market includes the following segments:

           Type

  • Amipril

  • Quinapril

  • Cilazapril

  • Benazepril

          Distribution Channel 

  • Hospital

  • Pharmacies

            Application

  • Hypertension

  • Heart Failure

  • Chronic Kidney Disorder
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Prils Market - Regional Analysis

North American Market Forecast

The prils market in North America is projected to be the largest with a share of about 41% by the end of 2035. The growth of the market can be attributed majorly to the increasing cases of obesity. For instance, the chance of developing hypertension and other cardiovascular disorders increases with obesity, which could result in a rise in the demand for hypertension drugs.

Further, the growing healthcare infrastructure in the region, along with the high prevalence of neurological disorders, is also anticipated to contribute to the market growth in the region. According to estimates, between 2017 and 2020, more than 40% of US people were obese, making it one of the most prevalent health issues in the country.

European Market Statistics

Europe industry is predicted to account for largest revenue share of 31% by 2035. The growth of the market can be attributed majorly to the increasing initiatives to assist the expansion of generic medications through pricing and reimbursement. Generic prils may be used more frequently as a result, which could raise demand for these drugs.

In addition, the region's favorable government policies and surging expenditure on research and development activities are also anticipated to boost market growth during the forecast period.

Prils Market size
Get Strategic Analysis by Region Now: Request Free Sample PDF

Prils Market Players:

    • Teva Pharmaceuticals Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Boehringer Ingelheim International GmbH
    • Sun Pharmaceuticals Industries Ltd.
    • Pfizer Inc.
    • Mylan N.V
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Manus Aktteva Biopharma LLP
    • Canagen Pharmaceuticals Inc.
    • Lupin Limited

Recent Developments

  • Lupin Limited entered into a contract with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Further, for the symptomatic management of people with non-dystrophic myotonic (NDM) diseases, Medis will market NaMuscla in Central and Eastern European nations.
  • Novartis AG collaborated with Dr. Reddy's Laboratories which is exclusive for certain of its well-known medications, such as the Voveran range, the Calcium range, and Methergine. Further, the agreement aims to increase patient’s access to these medications beyond present geographic boundaries.
  • Report ID: 4109
  • Published Date: Nov 21, 2025
  • Report Format: PDF, PPT
Festive Special Offer
$4550 $2450
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of prils is evaluated at USD 2.65 billion.

The global prils market size was worth more than USD 2.51 billion in 2025 and is poised to witness a CAGR of over 6.4%, crossing USD 4.67 billion revenue by 2035.

North America is anticipated to command a 41% share of the Prils Market by 2035, owing to the increasing cases of obesity.

Key players in the market include Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Mylan N.V, F. Hoffmann-La Roche Ltd., Novartis AG, Manus Aktteva Biopharma LLP, Canagen Pharmaceuticals Inc., Lupin Limited.

Prils Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Buy Now Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos